{ "schema_version": 1, "kind": "condition", "id": "type-2-diabetes", "name": "Type 2 diabetes mellitus", "category": "chronic", "sources": "ADA Standards of Care 2024 · Egyptian National Drug Formulary - Cardiovascular 2024 (atorvastatin monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (empagliflozin monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (losartan monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (gliclazide monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (sitagliptin monograph) · Glimepiride tablets US prescribing information, section 2 Dosage and Administration (DailyMed SetID fc9d8495-184c-3af1-e053-6394a90a5e29) · Metformin 500 mg film-coated tablets SmPC section 4.2 (eMC product 13160): \"The usual starting dose is 500 mg or 850 mg metformin hydrochloride 2 or 3 times daily given during or after meals.\" The label's own adult ceiling is higher than the maximum shown here - \"The maximum recommended dose of metformin hydrochloride is 3 g daily, taken as 3 divided doses\" - while its paediatric ceiling from 10 years of age is the 2 g daily shown here. · WHO EML 2023 · Type 2 Diabetes - StatPearls - NCBI Bookshelf - disease-level clinical article (type-2-diabetes-full.txt) · Egyptian National Drug Formulary - Endocrine System 2024 (acarbose monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (pioglitazone monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (acetylsalicylic acid monograph, management of cardiovascular diseases) · Egyptian National Drug Formulary - Cardiovascular 2024 (ezetimibe monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (glargine long-acting insulin monograph)", "review_status": "reviewed", "verified_against": "Egyptian National Drug Formulary - Cardiovascular 2024 (atorvastatin monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (empagliflozin monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (losartan monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (gliclazide monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (sitagliptin monograph) · Glimepiride tablets US prescribing information, section 2 Dosage and Administration (DailyMed SetID fc9d8495-184c-3af1-e053-6394a90a5e29) · Metformin 500 mg film-coated tablets SmPC section 4.2 (eMC product 13160): \"The usual starting dose is 500 mg or 850 mg metformin hydrochloride 2 or 3 times daily given during or after meals.\" The label's own adult ceiling is higher than the maximum shown here - \"The maximum recommended dose of metformin hydrochloride is 3 g daily, taken as 3 divided doses\" - while its paediatric ceiling from 10 years of age is the 2 g daily shown here. · Type 2 Diabetes - StatPearls - NCBI Bookshelf - disease-level clinical article (type-2-diabetes-full.txt) · Egyptian National Drug Formulary - Endocrine System 2024 (acarbose monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (pioglitazone monograph) · Egyptian National Drug Formulary - Cardiovascular 2024 (acetylsalicylic acid monograph, management of cardiovascular diseases) · Egyptian National Drug Formulary - Cardiovascular 2024 (ezetimibe monograph) · Egyptian National Drug Formulary - Endocrine System 2024 (glargine long-acting insulin monograph)", "verified_date": "2026-08", "treatments": [ { "id": 1767, "generic": "Metformin", "line": 1, "is_adjunct": false, "form": "oral.solid", "strength_mg": 500.0, "adult_dose": "500 mg orally twice or three times daily with or after meals, titrate to max 2000 mg daily", "adult_duration": "long-term", "dose_source": "Metformin 500 mg film-coated tablets SmPC section 4.2 (eMC product 13160): \"The usual starting dose is 500 mg or 850 mg metformin hydrochloride 2 or 3 times daily given during or after meals.\" The label's own adult ceiling is higher than the maximum shown here - \"The maximum recommended dose of metformin hydrochloride is 3 g daily, taken as 3 divided doses\" - while its paediatric ceiling from 10 years of age is the 2 g daily shown here.", "rationale": "Biguanide that lowers blood glucose mainly by reducing hepatic glucose output and improving peripheral insulin sensitivity; first-line oral therapy for type 2 diabetes because it lowers glucose without causing weight gain or hypoglycaemia.", "cautions": [ "Avoid if eGFR < 30.", "Withhold during acute illness, dehydration, or contrast imaging.", "GI upset is common - titrate slowly and take with food." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Children aged 10 years and over: initial 500 mg once daily with or after meals, titrate to max 2000 mg daily", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": [ { "label": "10 years and over", "age_min_months": 120, "age_max_months": 216, "dose_text": "500 mg once daily with or after meals to start, titrated to a maximum of 2000 mg daily" } ], "peds_doses": null, "brands": [ { "trade_name": "METFORMIN-EL NASR 500MG 200 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EL NASR", "price_egp": 26.0, "pack_count": 200, "unit_price": 0.13, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIAPHAGE 500MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHAROPHARMA", "price_egp": 4.0, "pack_count": 20, "unit_price": 0.2, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "AMOPHAGE 500MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMOUN", "price_egp": 10.5, "pack_count": 30, "unit_price": 0.35, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CIDOPHAGE 500 MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CID", "price_egp": 11.0, "pack_count": 10, "unit_price": 1.1, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLUCOPHAGE 500 MG 50 F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MINA PHARM > MERCK SANTE-FRANCE", "price_egp": 60.0, "pack_count": 50, "unit_price": 1.2, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "KELVAMET MR 500 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "BIOMED", "price_egp": 54.0, "pack_count": 30, "unit_price": 1.8, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ANDOGLYCEMIC XR 500MG 30 EXT. REL. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ANDALOUS PHARMA", "price_egp": 24.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "METIANORMIN 500 MG 30 EXT. REL. F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "WADI ELNEEL BENTA", "price_egp": 54.0, "pack_count": null, "unit_price": null, "strength_mg": 500.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1774, "generic": "Referral & safety-netting (no drug therapy)", "line": 1, "is_adjunct": false, "form": null, "strength_mg": null, "adult_dose": null, "adult_duration": null, "dose_source": "Type 2 Diabetes - disease-level clinical article (type-2-diabetes-full.txt)", "rationale": "Carries the referral criteria and warning signs for this condition, which apply whichever treatment is chosen.", "cautions": [ "RED FLAG - Refer to an ophthalmologist, nephrologist, cardiologist, and vascular surgeon for diabetes complications.", "Iron or vitamin B12 deficiency anaemia falsely raises HbA1c, which limits its use for diagnosis in populations where anaemia is common.", "HbA1c is also unreliable in sickle cell disease, pregnancy, haemodialysis, recent blood loss or transfusion, and erythropoietin therapy - use a plasma glucose test instead in these patients.", "Arrange fundal examination as guidelines direct, and check urine albumin excretion at least twice a year.", "Teach every patient the symptoms of hypoglycaemia - fast heartbeat, sweating, confusion - and the action required: 15 to 20 grams of carbohydrate.", "Hyperglycaemic hyperosmolar state and hyperglycaemic coma are acute emergencies of this disease alongside hypoglycaemia and ketoacidosis.", "Every patient with diabetes should be actively encouraged to stop smoking and to abstain from alcohol.", "RED FLAG - Before an oral glucose tolerance test the patient needs at least 150 g of carbohydrate daily for 3 to 5 days and must not be taking steroids or thiazide diuretics, which distort the result." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": null, "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [], "condition_id": "type-2-diabetes" }, { "id": 1768, "generic": "Gliclazide", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": 80.0, "adult_dose": "40-80 mg once daily with breakfast, up to 320 mg/day divided", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (gliclazide monograph)", "rationale": "Sulfonylurea that stimulates pancreatic beta-cell insulin secretion to lower blood glucose; an inexpensive option when metformin alone is insufficient, though it carries a hypoglycaemia and weight-gain risk.", "cautions": [ "Caution in the elderly, and in mild to moderate renal or hepatic impairment - for both, the ENDF gliclazide monograph asks for no change of dose but for care and close monitoring.", "CONTRAINDICATED in severe renal or hepatic impairment: the same monograph bars its use where impairment is severe, under both its Altered Kidney Function and Hepatic Impairment headings, and names severe renal or hepatic impairment among its contra-indications.", "Weight gain is common.", "There is a hypoglycaemia risk - counsel the patient." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not used in children", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "GLICLA 80MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EIPICO", "price_egp": 12.0, "pack_count": 30, "unit_price": 0.4, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLIPICRONE 80MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMRIYA", "price_egp": 8.2, "pack_count": 20, "unit_price": 0.41, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIANORMAL 80MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA", "price_egp": 8.5, "pack_count": 20, "unit_price": 0.42, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIABETRON 80MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMOUN", "price_egp": 9.0, "pack_count": 20, "unit_price": 0.45, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIABYL 80MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MEMPHIS", "price_egp": 9.0, "pack_count": 20, "unit_price": 0.45, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLICLAZIDE-SIGMA 80MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 15.0, "pack_count": 30, "unit_price": 0.5, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "SERVICLAZID 80MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVARTIS", "price_egp": 5.5, "pack_count": 10, "unit_price": 0.55, "strength_mg": 80.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1769, "generic": "Empagliflozin", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": 10.0, "adult_dose": "10 mg once daily, may increase to 25 mg", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Cardiovascular 2024 (empagliflozin monograph)", "rationale": "SGLT2 inhibitor that lowers blood glucose by blocking renal glucose reabsorption and promoting urinary glucose excretion; also used for its cardiovascular and renal protective effects in type 2 diabetes.", "cautions": [ "There is a risk of euglycaemic DKA - withhold during acute illness or fasting.", "Genital mycotic infection is common - counsel on hygiene.", "Volume depletion can occur in the elderly or on diuretics." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not used in children", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "EMPAGLIMAX 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HIKMA PHARMA", "price_egp": 154.5, "pack_count": 30, "unit_price": 5.15, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ATCOGLIFLOZIN 10 MG 30 F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ATCO PHARMA", "price_egp": 180.0, "pack_count": 30, "unit_price": 6.0, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLIMPACARE 10 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MULTICARE", "price_egp": 180.0, "pack_count": 30, "unit_price": 6.0, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "FAGLOZINO 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DEBEIKY > INSPIRE PHARMACEUTICAL COMPANY", "price_egp": 186.0, "pack_count": 30, "unit_price": 6.2, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "MELLITOFIX 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 204.0, "pack_count": 30, "unit_price": 6.8, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EMPAGLUTECH 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MASH PREMIERE", "price_egp": 231.0, "pack_count": 30, "unit_price": 7.7, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLEMPOZIN 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > SOVALUE PHARMA", "price_egp": 240.0, "pack_count": 30, "unit_price": 8.0, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "JARDIANCE 10 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "BOEHRINGER INGELHEIM > UNITED COMPANY FOR DISTRIBUTION", "price_egp": 626.0, "pack_count": 30, "unit_price": 20.87, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1775, "generic": "Liraglutide", "line": 2, "is_adjunct": false, "form": "injection", "strength_mg": 6.0, "adult_dose": "Initial S.C: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily; if optimal glycemic response is not achieved after an additional week of treatment, may increase further to 1.8 mg once daily", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Endocrine", "rationale": "GLP-1 receptor agonist that reduces cardiovascular events and mortality in type 2 diabetes patients with CV disease; also reduces body weight and blood pressure.", "cautions": [ "Discontinue if symptoms of acute pancreatitis occur, such as persistent severe abdominal pain.", "Liraglutide may cause thyroid C-cell tumors at clinically relevant doses; counsel patients regarding potential risk of MTC.", "Hypoglycemia risk is increased when combined with sulfonylureas.", "Avoid use in pregnancy; no human data, toxicity in animal models." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Children aged 10 years and above: same titration as adults (0.6 mg to 1.8 mg once daily)", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": [ { "label": "10 years and over", "age_min_months": 120, "age_max_months": 216, "dose_text": "Same titration as adults: 0.6 mg to 1.8 mg once daily" } ], "peds_doses": null, "brands": [ { "trade_name": "VICTOZA 18MG/3 ML 2 PRE-FILLED PEN S.C.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVO NORDISK > UNITED COMPANY FOR DISTRIBUTION", "price_egp": 1752.0, "pack_count": null, "unit_price": null, "strength_mg": 18.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "SAXENDA 18MG/3 ML 1 PRE-FILLED PEN S.C.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVO NORDISK > UNITED COMPANY FOR DISTRIBUTION", "price_egp": 1970.0, "pack_count": null, "unit_price": null, "strength_mg": 18.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null }, { "trade_name": "SAXENDA 18MG/3 ML 3 PRE-FILLED PEN S.C.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "NOVO NORDISK > UNITED COMPANY FOR DISTRIBUTION", "price_egp": 5910.0, "pack_count": null, "unit_price": null, "strength_mg": 18.0, "exact_strength": false, "exact_form": false, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1776, "generic": "Acarbose", "line": 2, "is_adjunct": false, "form": "oral.solid", "strength_mg": 50.0, "adult_dose": "Initial 25 mg 3 times daily with the start of each main meal (may start once daily); maintenance 50 to 100 mg 3 times daily reached after a 4 to 8 week interval", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (acarbose monograph)", "rationale": "The disease article names alpha-glucosidase inhibitors as a therapy option following metformin, and the ENDF places acarbose exactly there - for patients with metformin contraindications or intolerance.", "cautions": [ "Hypersensitivity to acarbose or any component of the formulation", "Diabetic ketoacidosis, cirrhosis, hepatic or renal severe impairment", "Inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, patients predisposed to intestinal obstruction", "Maximum dose for patients 60 kg or less: 50 mg 3 times daily; for patients above 60 kg: 100 mg 3 times daily", "Only 50 mg tablets are registered in Egypt, so the ENDF's 25 mg starting dose means half a tablet." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "ENDF: not recommended in pediatrics.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "OPICROCEED 50 MG 10 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EL-OBOUR", "price_egp": 7.5, "pack_count": 10, "unit_price": 0.75, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1770, "generic": "Sitagliptin", "line": 3, "is_adjunct": false, "form": "oral.solid", "strength_mg": 100.0, "adult_dose": "100 mg once daily", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (sitagliptin monograph)", "rationale": "DPP-4 inhibitor that prolongs incretin hormone activity to enhance glucose-dependent insulin secretion and suppress glucagon; a weight-neutral option with low hypoglycaemia risk when added to other glucose-lowering therapy.", "cautions": [ "Reduce dose in renal impairment.", "Rare pancreatitis can occur - stop if severe abdominal pain.", "Sitagliptin is weight-neutral, with low hypoglycaemia risk as monotherapy." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not used in children", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "GLIPTADALO 100 MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ANDALOUS PHARMA", "price_egp": 120.0, "pack_count": 30, "unit_price": 4.0, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIBACURE 100MG 7 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > HOCHSTER PHARMACEUTICAL INDUSTRIES", "price_egp": 38.5, "pack_count": 7, "unit_price": 5.5, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "PHARMABETIC 100 MG 30 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ADWIA", "price_egp": 253.5, "pack_count": 30, "unit_price": 8.45, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "JANAGLIP 100 MG 28 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HIKMA PHARMA", "price_egp": 262.0, "pack_count": 28, "unit_price": 9.36, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLAPTIVIA 100 MG 30 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MARCYRL PHARMACEUTICAL INDUSTRIES (MPI)", "price_egp": 303.0, "pack_count": 30, "unit_price": 10.1, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "JANUVIA 100MG 28 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK SHARP & DOHME > SOFICOPHARM", "price_egp": 510.0, "pack_count": 28, "unit_price": 18.21, "strength_mg": 100.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1773, "generic": "Glimepiride", "line": 3, "is_adjunct": false, "form": "oral.solid", "strength_mg": 2.0, "adult_dose": "1-2 mg once daily with breakfast or the first meal of the day. Increase by 1-2 mg no more often than every 1-2 weeks according to glycaemic response. Maximum 8 mg once daily", "adult_duration": "long-term", "dose_source": "Glimepiride tablets US prescribing information, section 2 Dosage and Administration (DailyMed SetID fc9d8495-184c-3af1-e053-6394a90a5e29)", "rationale": "The sulfonylurea Egypt stocks most widely - 51 live products from 3.50 EGP - and once daily rather than twice. Gliclazide MR above it remains first choice of the two because it causes less hypoglycaemia; this is the alternative when gliclazide is unavailable or once-daily dosing matters for adherence.", "cautions": [ "HYPOGLYCAEMIA is the main risk and it can be prolonged. Start at 1 mg, not 2 mg, in the elderly and in renal impairment, and titrate slowly - the label says so explicitly for both groups.", "Take it with the first meal. A dose taken without food is the commonest way a sulfonylurea causes a hypo.", "Warn about weight gain, and about driving and hypoglycaemia awareness.", "Do not combine with gliclazide or any other sulfonylurea - they are the same mechanism and the row above is an alternative to this one, not a partner." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not for children. Type 2 diabetes in a child or adolescent is a specialist referral, and metformin is the only oral agent licensed below 18.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "GLIMITOID 2MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 15.0, "pack_count": 30, "unit_price": 0.5, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GEDIMADEL 2MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "JEDCO INT. CO. FOR PHARMACEUTICALS", "price_egp": 15.75, "pack_count": 30, "unit_price": 0.53, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "REGLIDIB 2MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 18.0, "pack_count": 30, "unit_price": 0.6, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLIMADEL 2MG 30 F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DELTA PHARMA", "price_egp": 20.25, "pack_count": 30, "unit_price": 0.68, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIABETO 2 MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HI-PHARM", "price_egp": 16.0, "pack_count": 20, "unit_price": 0.8, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIABENOR 2 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EGPI > ABBOTT", "price_egp": 36.0, "pack_count": 30, "unit_price": 1.2, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DOLCYL 2MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MUP", "price_egp": 48.0, "pack_count": 30, "unit_price": 1.6, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "AMARYL 2 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 78.0, "pack_count": 30, "unit_price": 2.6, "strength_mg": 2.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1777, "generic": "Pioglitazone", "line": 3, "is_adjunct": false, "form": "oral.solid", "strength_mg": 15.0, "adult_dose": "Initial 15 or 30 mg once daily, increased up to 45 mg once daily if needed", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (pioglitazone monograph)", "rationale": "Named by the disease article as an option especially for patients with fatty liver disease, which is common alongside type 2 diabetes in this population. The ENDF indicates it as second- or third-line adjunct to diet and exercise.", "cautions": [ "Cardiac failure or history of cardiac failure (NYHA stages I to IV)", "Hepatic impairment; diabetic ketoacidosis", "Current bladder cancer or a history of bladder cancer; uninvestigated macroscopic haematuria", "Patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). Pioglitazone should be discontinued, if no adequate response." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "ENDF: safety and efficacy of pioglitazone in pediatric patients have not been established.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "HI-GLITAZONE 15MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "HI-PHARM", "price_egp": 27.6, "pack_count": 30, "unit_price": 0.92, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLUSTAZON 15MG 21 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CHEMIPHARM", "price_egp": 23.25, "pack_count": 21, "unit_price": 1.11, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "DIABETIN 15 MG 30 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "UNIPHARMA", "price_egp": 75.0, "pack_count": 30, "unit_price": 2.5, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ENSUDYNE 15MG 7 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MUP", "price_egp": 21.6, "pack_count": 7, "unit_price": 3.09, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLUSTIN 15MG 7 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "TAKEDA", "price_egp": 39.75, "pack_count": 7, "unit_price": 5.68, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ACTOS 15MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARAB PHARMACEUTICAL MANUFACTURING CO. > HIKMA PHARMA", "price_egp": 273.0, "pack_count": 30, "unit_price": 9.1, "strength_mg": 15.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1780, "generic": "Insulin glargine", "line": 3, "is_adjunct": false, "form": "injection", "strength_mg": null, "adult_dose": "Once-daily at any time of the day, preferably at the same time every day, dose is determined according to individual patient's needs. In type 2 diabetes, to be taken alone or in combination with other antidiabetic agents", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - Endocrine System 2024 (glargine long-acting insulin monograph)", "rationale": "The disease article lists insulin among the therapies available after metformin. No dosing document in this project states a number for any insulin: all five ENDF insulin monographs say requirements vary dramatically between patients and require titration under supervision, so the formulary's own individualisation wording is printed here instead of a dose. Glargine is the one whose ENDF indication names type 2 diabetes and gives the once-daily basal regimen.", "cautions": [ "Note: Insulin glargine is a long-acting insulin. Insulin requirements vary dramatically between patients, and therapy requires dosage adjustments with careful medical supervision.", "Hypersensitivity to insulin glargine or any component of the formulation; hypoglycemia", "Transferring between types of insulins or in additions of other antidiabetics: An initial dose reduction of 20% should be considered in order to minimize the risk of hypoglycemia, then adjust dose according to patient needs.", "Renal or hepatic impairment: glucose monitoring is to be intensified and the insulin dose adjusted on an individual basis. Dosage reduction may be needed." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "ENDF: indicated from 2 years of age, but no numeric paediatric dose is stated - insulin requirements vary dramatically between patients and require dosage adjustments with careful medical supervision.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "ABASAGLAR 100 I.U./ML 5 CARTRIDGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ELI LILLY > AKHNATON TRADING & DISTRIBUTION", "price_egp": 645.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ABASAGLAR KWIKPEN 100 I.U./ML 5 PENS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ELI LILLY > AKHNATON TRADING & DISTRIBUTION", "price_egp": 725.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "GLARGIVIN 100 I.U./ML 5 CARTRIDGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EVA PHARMA", "price_egp": 910.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LANTUS 100 I.U./ML 5 CARTRIDGES", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 1107.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LANTUS SOLOSTAR 100 I.U./ML 5 PENS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 1244.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TOUJEO SOLOSTAR 300 I.U./ML 1.5 ML 3 PENS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 1416.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "TOUJEO SOLOSTAR 300 I.U./ML 1.5 ML 5 PENS", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SANOFI", "price_egp": 2360.0, "pack_count": null, "unit_price": null, "strength_mg": null, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1771, "generic": "Atorvastatin", "line": 1, "is_adjunct": true, "form": "oral.solid", "strength_mg": 20.0, "adult_dose": "20 mg once daily", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Cardiovascular 2024 (atorvastatin monograph)", "rationale": "NICE NG238 routes people with type 2 diabetes aged 25-84 through QRISK3 (1.1.8) and offers atorvastatin 20 mg for primary prevention at a 10-year QRISK3 score of 10 percent or more (1.6.7); most type 2 diabetics over 40 cross that threshold. The Egyptian formulary carries the same 20 mg once-daily primary-prevention dose and lists atorvastatin on the EML. This is the second line of the prescription, not an optional extra. (NG238 replaced CG181, which NICE has since withdrawn.)", "cautions": [ "This is a risk-based decision, not automatic: NICE routes type 2 diabetes through QRISK3 and treats at 10 percent or more over 10 years.", "Contraindicated in active liver failure and decompensated cirrhosis.", "Stop promptly and check creatine kinase if there are severe muscle symptoms or unexplained fatigue.", "Avoid in pregnancy and while breastfeeding.", "Do not offer fibrates, nicotinic acid, bile acid sequestrants or omega-3 compounds instead - NICE NG238 1.12.2-1.12.5 recommends against all four (CG181, the earlier citation, has been withdrawn and replaced by NG238)." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not used for type 2 diabetes in children. The formulary's only paediatric indication is familial hypercholesterolaemia from 10 years.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "ANTICHOL 20 MG 10 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "JEDCO INT. CO. FOR PHARMACEUTICALS", "price_egp": 14.4, "pack_count": 10, "unit_price": 1.44, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LIRIMAR 20 MG 10 CAPS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RIVA PHARMA S.A.E.", "price_egp": 15.0, "pack_count": 10, "unit_price": 1.5, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LIPOVAST 20MG 7 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MISR", "price_egp": 11.5, "pack_count": 7, "unit_price": 1.64, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "SIGMALIP 20 MG 10 F.C.TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 24.0, "pack_count": 10, "unit_price": 2.4, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LIPOSEDRA 20 MG 30 F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DELTA PHARMA > SUECAL PHARMA", "price_egp": 111.0, "pack_count": 30, "unit_price": 3.7, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ATOR 20 MG 10 F.C.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EIPICO", "price_egp": 79.0, "pack_count": 10, "unit_price": 7.9, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ATCOLIPOX 20 MG 30 CHEW. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ATCO PHARMA", "price_egp": 72.0, "pack_count": null, "unit_price": null, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "HIPOLIXAVAST 20 MG 30 CHEW. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "EGPI", "price_egp": 127.5, "pack_count": null, "unit_price": null, "strength_mg": 20.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1772, "generic": "Losartan", "line": 1, "is_adjunct": true, "form": "oral.solid", "strength_mg": 50.0, "adult_dose": "25-50 mg once daily, titrated to 100 mg/day in 1-2 divided doses", "adult_duration": "long-term", "dose_source": "Egyptian National Drug Formulary - Cardiovascular 2024 (losartan monograph)", "rationale": "The Egyptian formulary lists treatment of diabetic nephropathy in type 2 diabetes mellitus as a named indication for losartan, with the same dose range as for hypertension. Once there is albuminuria the diabetic prescription is metformin plus a statin plus this.", "cautions": [ "CONTRAINDICATED in pregnancy - the same rule as for ACE inhibitors.", "Check creatinine and potassium 1-2 weeks after starting and after each dose increase; hyperkalaemia is listed at 1-10 percent.", "Do not combine with aliskiren in a patient with diabetes or renal impairment.", "Avoid in bilateral renal artery stenosis.", "Start at 25 mg in hepatic impairment and in patients over 75." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "The formulary's paediatric dosing is for hypertension from 6 years and is weight-banded: 20 to under 50 kg, 25 mg once daily (maximum 50 mg/day); 50 kg and over, 50 mg once daily (maximum 100 mg/day). Not for paediatric type 2 diabetes.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "LOSAPOTT 50 MG 14 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHAROPHARMA", "price_egp": 21.6, "pack_count": 14, "unit_price": 1.54, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LOSTAPRESSIN 50 MG 21 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "DELTA PHARMA", "price_egp": 33.0, "pack_count": 21, "unit_price": 1.57, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "AMOSAR 50MG 30 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMOUN", "price_egp": 51.0, "pack_count": 30, "unit_price": 1.7, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LOSARTAN-AMRIYA 50MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "AMRIYA", "price_egp": 21.6, "pack_count": 10, "unit_price": 2.16, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LOSARMEPHA-50 MG 14 F.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA > ACINO", "price_egp": 32.4, "pack_count": 14, "unit_price": 2.31, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LOZAPRESS 50MG 14 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "SIGMA", "price_egp": 32.4, "pack_count": 14, "unit_price": 2.31, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LOSAR 50MG 28 F.C. TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "UNIPHARMA", "price_egp": 82.0, "pack_count": 28, "unit_price": 2.93, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "COZAAR 50MG 14 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK SHARP & DOHME", "price_egp": 74.5, "pack_count": 14, "unit_price": 5.32, "strength_mg": 50.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1778, "generic": "Acetylsalicylic acid", "line": 1, "is_adjunct": true, "form": "oral.solid", "strength_mg": 75.0, "adult_dose": "75 to 150 mg once daily", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - Cardiovascular 2024 (acetylsalicylic acid monograph, management of cardiovascular diseases)", "rationale": "The disease article puts aspirin in SECONDARY prevention - alongside lipid lowering and ACE/ARB therapy - as part of what makes the vascular complications of diabetes manageable. It does not support aspirin for primary prevention in diabetes, and the ENDF's own vascular indications are all established disease.", "cautions": [ "The ENDF vascular indications are ischemic stroke, transient ischemic attack, acute coronary syndromes, secondary prevention after acute coronary syndromes, management of stable ischemic heart disease, and use after coronary artery bypass graft.", "Hypersensitivity to NSAIDS; patients with asthma, rhinitis, and nasal polyps", "Active peptic ulceration", "CrCl <10 mL/minute: Avoid use. May exacerbate uremic gastrointestinal and hematologic symptoms." ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "Not applicable - this row is for adults with type 2 diabetes and established cardiovascular disease.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": null, "peds_doses": null, "brands": [ { "trade_name": "AGGREX 75MG 60 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "RAMEDA", "price_egp": 33.0, "pack_count": 60, "unit_price": 0.55, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ASPOCID 75MG 20 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CID", "price_egp": 22.0, "pack_count": 20, "unit_price": 1.1, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ASPOCID 75MG 30 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CID", "price_egp": 33.0, "pack_count": 30, "unit_price": 1.1, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ASPIRIN-CHEMIPHARM 75 MG 30 CHEW.TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CHEMIPHARM", "price_egp": 12.0, "pack_count": null, "unit_price": null, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "RIVO 75 MG 30 CHEW. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ARAB DRUG COMPANY (ADCO)", "price_egp": 21.0, "pack_count": null, "unit_price": null, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ASPOCID PAEDIATRIC 75MG 30 CHEW. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "CID", "price_egp": 35.0, "pack_count": null, "unit_price": null, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EZACARD 75 MG 30 E.C. TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MULTI-APEX", "price_egp": 51.0, "pack_count": null, "unit_price": null, "strength_mg": 75.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" }, { "id": 1779, "generic": "Ezetimibe", "line": 2, "is_adjunct": true, "form": "oral.solid", "strength_mg": 10.0, "adult_dose": "10 mg once daily", "adult_duration": null, "dose_source": "Egyptian National Drug Formulary - Cardiovascular 2024 (ezetimibe monograph)", "rationale": "The card carried atorvastatin alone. The disease article's lipid target for a diabetic patient with established atherosclerotic disease is an LDL-C below 70 mg/dl, and it names ezetimibe as what to add when the statin does not get there. The ENDF indicates ezetimibe for exactly that - adjunctive therapy to diet and a statin.", "cautions": [ "Concomitant use with an HMG-CoA reductase inhibitor (statin) in patients with active hepatic disease or unexplained persistent elevations in serum transaminases", "Pregnancy and breastfeeding (when used concomitantly with a statin)", "Moderate to severe hepatic impairment: use not recommended" ], "peds_mgkg_low": null, "peds_mgkg_high": null, "peds_max_mg": null, "peds_basis": null, "peds_unit": null, "peds_note": "ENDF: children 10 years and above and adolescents, 10 mg once daily in combination with simvastatin.", "peds_min_weight_kg": null, "peds_max_weight_kg": null, "peds_age_min_months": null, "peds_age_max_months": null, "peds_age_bands": [ { "label": "10 years and over", "age_min_months": 120, "age_max_months": 216, "dose_text": "10 mg once daily in combination with simvastatin" } ], "peds_doses": null, "brands": [ { "trade_name": "LOWTIMIB 10 MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "PHAROPHARMA", "price_egp": 11.5, "pack_count": 10, "unit_price": 1.15, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CHOLSTOP 10MG 30 TAB", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MUP", "price_egp": 41.0, "pack_count": 30, "unit_price": 1.37, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EZETIMIBE 10MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "BORG", "price_egp": 14.4, "pack_count": 10, "unit_price": 1.44, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "LIPIDNORM 10 MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "OCTOBER PHARMA", "price_egp": 14.4, "pack_count": 10, "unit_price": 1.44, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ZETAMIBE 10 MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "ADWIA", "price_egp": 34.8, "pack_count": 10, "unit_price": 3.48, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "ZETLIP 10MG 10 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "BIORIGINAL INTERNATIONAL GROUP PHARMA EGYPT", "price_egp": 35.0, "pack_count": 10, "unit_price": 3.5, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "CHOLETIMB 10 MG 14 TABS.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MARCYRL PHARMACEUTICAL INDUSTRIES (MPI)", "price_egp": 65.0, "pack_count": 14, "unit_price": 4.64, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null }, { "trade_name": "EZETROL 10MG 7 TAB.", "scientific_name": null, "normalized_ingredient": null, "manufacturer": "MERCK SHARP & DOHME > GLOBAL NAPI PHARMACEUTICALS", "price_egp": 90.0, "pack_count": 7, "unit_price": 12.86, "strength_mg": 10.0, "exact_strength": true, "exact_form": true, "discontinued": false, "also_contains": null } ], "condition_id": "type-2-diabetes" } ] }